Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 6/20 | 0.46 |
| ▸ | CNR1 | P21554 | 3/20 | 0.46 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | AOC2 | O75106 | 2/20 | 0.31 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.31 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.31 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.31 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.31 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.31 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13392840 | 0.90 | CNR2 (0.40) | CNR2CNR1AOC2PSEN1PSEN2 | |
| SCHEMBL13392949 | 0.88 | CNR2 (0.34) | CNR2CNR1 | |
| SCHEMBL12289431 | 0.85 | CNR2 (0.36) | CNR2CNR1PIK3CDPSEN1PSEN2 | |
| SCHEMBL10177092 | 0.85 | CNR2 (0.43) | CNR2CNR1PIK3CDAOC2MAOA | |
| SCHEMBL766752 | 0.85 | CNR2 (0.47) | CNR2CNR1PIK3CD | |
| SCHEMBL10146289 | 0.83 | CNR2 (0.41) | CNR2CNR1 | |
| SCHEMBL352817 | 0.83 | CNR2 (0.52) | CNR2CNR1AOC2MAOA | |
| SCHEMBL766875 | 0.78 | CNR2 (0.43) | CNR2CNR1 | |
| SCHEMBL12289441 | 0.78 | PSEN1 (0.32) | CNR2CNR1PSEN1PSEN2APH1B | |
| SCHEMBL10147821 | 0.78 | CNR2 (0.40) | CNR2CNR1PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8846936-B2 | Sulfonyl compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-09-30 | — | — | US | disclosed |
| US-20130184315-A1 | SULFONYL COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-07-18 | — | — | US | disclosed |
| WO-2011109324-A1 | TETRAZOLE COMPOUNDS WHICH SELECTIVELY MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130184315-A1 | SULFONYL COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | CNR2, CNR1, GPR52 | CNR2 1/4885CNR1 2/4885PIK3CD 2375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.